Table 1 Clinical course of patients with metastatic lesions
From: Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma
Identifier | Primary tumour and therapy | Metastases | Therapy | Death |
|---|---|---|---|---|
4330/99 2854/99 | 1/96 enucleation | 6/98 liver metastases 1/99 lung metastases | Fotemustine treosulphan/gemcitabine | 1/00 |
800/98 | 3/91 enucleation | 1/96 spleen metastases 8/96 liver metastases | Splenectomie interferon fotemustine | Date last seen 10/97 |
8202/97 | 96 | 9/96 liver and lung metastases | Fotemustine, IL-2 dacarbacin | 1/98 |
9057/97b | 12/89 radiation | 8/94 lung metastases 97 abdominal metastases 98 brain metastases | Combined IL-2 and interferon alpha polychemotherapy | 98 |
9059/97 | 91 | 5/97 skin and liver metastases 98 bone metastases | Fotemustine IL-2 Interferon alpha | 11/98 |
1709/94 | 87 operation | 9/93 brain, lung, liver metastases | Radiatio fotemustine | 1/95 |
5368/92 | 87 | 2/92 liver metastases 11/92 cutaneous metastases | Interferon alpha McClay | 5/93 |
15/99-2 | 1/99 enucleation | 6/00 liver and lung metastases | Treosulphan and gemcitabine 10/01 fotemustine | 9/02 |
